MUC1 is a highly glycosylated, type I transmembrane protein expressed by normal ductal epithelial cells of the pancreas, breast, lung, and gastrointestinal tract, and overexpressed in many cases of adenocarcinoma. We down-regulated MUC1 expression by RNA interference and investigated the effects on malignant and metastatic potential of a human pancreatic cancer cell line, S2-013. MUC1-suppressed clones, S2-013.MTII.C1 and S2-013.MTII.C2, were established by targeting a sequence 3,151 bp from the initiation codon and characterized in vitro for proliferation, invasion, and adhesion. We evaluated the effects of MUC1 suppression in vivo on tumor growth and metastatic properties following implantation into the cecum or pancreas of athymic mice. MUC1-suppressed clones showed significantly decreased proliferation in vitro and in vivo. Global gene expression was evaluated by oligonucleotide microarray analysis. Surprisingly, genes predicted to increase doubling times (cyclin B1 and cyclin D3) were overexpressed in MUC1-suppressed clones. There were alterations in expression of several genes that may affect the malignant properties of pancreatic cancer. Adhesion of MUC1-suppressed cells in vitro to type IV collagen and fibronectin was slightly increased, and adhesion was slightly decreased to type I collagen and laminin. Results of implantation to cecum and pancreas showed significant reduction of metastasis to lymph nodes, lung, or peritoneal sites compared with S2-013.gfp-neo control cells. These results support the hypothesis that MUC1 contributes significantly to growth and metastasis, and that down-regulation of MUC1 protein expression decreases the metastatic potential of pancreatic adenocarcinoma.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1197DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
12
muc1-suppressed clones
12
rna interference
8
human pancreatic
8
metastatic potential
8
implantation cecum
8
cecum pancreas
8
type collagen
8
muc1
6
interference suppression
4

Similar Publications

AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility.

Sci Rep

January 2025

Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Pancreatic ductal adenocarcinoma lacks suitable biomarkers for early diagnosis of disease. In gene panels developed for early diagnosis of pancreatic cancer, high AHNAK2 mRNA expression was one possible biomarker. In silico analysis of published human sample datasets (n = 177) and ex vivo analysis of human plasma samples (n = 30 PDAC with matched 30 healthy control) suggested AHNAK2 could be a diagnostic biomarker.

View Article and Find Full Text PDF

Root-cause analysis of mortality after pancreatic resection in a nationwide cohort.

HPB (Oxford)

December 2024

Depts. of Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital Nieuwegein, University Medical Center Utrecht, the Netherlands. Electronic address:

Background: This study evaluates leading causes of in-hospital mortality after pancreatic resection nationwide to determine areas for improvement.

Methods: This observational cohort study included all in-hospital mortality after pancreatic resection in the Netherlands (2014-2019). Each fatality was considered to be caused by local complications (i.

View Article and Find Full Text PDF

Rationale And Objectives: The purpose of this study was to demonstrate the impact of postoperative adjuvant transarterial chemoembolization (TACE) on the prognosis of patients with macrotrabecular-massive hepatocellular carcinoma (MTM-HCC).

Materials And Methods: This retrospective study used the clinical records of patients with resected MTM-HCC with/without adjuvant TACE at three centers between January 2015 and December 2022. The primary end point was recurrence free survival (RFS).

View Article and Find Full Text PDF

Background: Identifying past, present, and future temporal trends in gallbladder and biliary tract cancer (GBTC) can increase public awareness and promote changes in prevention and treatment strategies.

Methods: The incidence and death rates of GBTC between 1990 and 2021 were extracted from the Global Burden of Disease 2021 study and assessed according to country, region, year, age, and sex. Time trends were measured using the average annual percentage change (AAPC) and projections of the burden of disease for 2022-2045 were made using the Bayesian age-period-cohort model.

View Article and Find Full Text PDF

Background: Clinicians lack robust data on quality of life and social functioning after pancreatectomy limiting their ability guide patient decision-making aligned with patients' goals of care.

Methods: In this cross-sectional survey study, we administered the European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30); pancreas-specific QLQ-PAN26; Patient-Reported Outcomes Measurement Information System (PROMIS™) Ability to Participate in Social Roles; and PROMIS™ Activities and social Isolation scales to all elective pancreatectomies (2021-2023). Results were compared to both normative data and between groups to determine factors predicting better QOL with a >10-12-point change considered clinically significant.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!